1. Introduction {#sec1-ijms-20-05139}
===============

Adenosine, in the extracellular milieu, is generated mainly via the degradation of adenosine 5′-triphosphate (ATP) released under stress conditions, to protect cells and tissues locally. Adenosine and ATP acting at different classes of receptors often have opposite effects in cell proliferation or cell death. ATP and other adenine nucleotides have antitumor effects via the activation of the P2Y~1~ receptor (P2Y~1~R) subtype \[[@B1-ijms-20-05139],[@B2-ijms-20-05139]\], whereas adenosine induces cancer cell proliferation and growth of many types of tumors via the activation of the A~2B~ adenosine receptor (AR) \[[@B3-ijms-20-05139],[@B4-ijms-20-05139],[@B5-ijms-20-05139],[@B6-ijms-20-05139],[@B7-ijms-20-05139],[@B8-ijms-20-05139],[@B9-ijms-20-05139],[@B10-ijms-20-05139]\]. The generation and degradation/removal of adenosine is a multi-step and balanced process in cells involving enzymes (Cluster of Differentiation 39 (CD39), CD73, CD26, adenosine deaminase, adenosine kinase, S-adenosyl homocysteine hydrolase) and nucleoside transporters \[[@B11-ijms-20-05139]\], which are not the main topic of this review. Although extracellular adenosine exerts its action via four G protein-coupled receptors (GPCRs), A~1~, A~2A~, A~2B~ and A~3~ \[[@B12-ijms-20-05139]\], in this review we will only focus on the importance of A~2B~AR signaling ([Figure 1](#ijms-20-05139-f001){ref-type="fig"}) in cancer progression and the rationale to use A~2B~AR antagonists as anticancer agents.

The importance of the A~2B~AR in cancer progression has only recently been revealed, despite the physiological role of adenosine in cardiac function being realized almost a century ago \[[@B13-ijms-20-05139]\]. Although A~2B~AR effects in brain slices were characterized in the early 1980s \[[@B14-ijms-20-05139]\], until recently the A~2B~AR has been poorly characterized in comparison to the other three ARs, which is at least in part due to the fact that A~2B~AR has low affinity for the endogenous agonist adenosine 1 (EC~50~ \~24 µM, [Figure 2](#ijms-20-05139-f002){ref-type="fig"}, [Table 1](#ijms-20-05139-t001){ref-type="table"}). Thus, it was assumed that A~2B~AR must have a minor physiological significance. However, increasing evidence has shown that there is a dramatic increase in extracellular adenosine concentration and a significant upregulation of A~2B~AR expression under many pathological conditions \[[@B15-ijms-20-05139],[@B16-ijms-20-05139],[@B17-ijms-20-05139]\], such as hypoxia, inflammation and cancer, which may indicate the critical role of A~2B~AR in many diseases. For example, adenosine concentration has been reported to increase 10-fold in patients with septic shock \[[@B18-ijms-20-05139]\]. Hypoxia-inducible factor 1 (HIF-1α) has been reported to up-regulate A~2B~AR expression on activated macrophages \[[@B19-ijms-20-05139]\]. Lan et al. \[[@B20-ijms-20-05139]\] found that hypoxia increased expression of A~2B~AR in human breast cancer cells through the transcriptional activity of HIF-1α. The discovery that A~2B~AR expression is significantly increased by HIF-1α strongly suggested its involvement in cancer promotion \[[@B20-ijms-20-05139],[@B21-ijms-20-05139],[@B22-ijms-20-05139],[@B23-ijms-20-05139]\]. In addition to its role in tumor growth, inhibition of A~2B~AR genetically or pharmacologically dramatically decreased lung metastasis after implantation of breast cancer cells into the mammary fat pad of immunodeficient mice \[[@B20-ijms-20-05139]\]. It has also been recently shown that bladder urothelial carcinoma expresses high levels of A~2B~AR, which is suggested to be associated with a poor patient prognosis \[[@B24-ijms-20-05139]\]. A tissue microarray of 232 breast cancer samples, that included 66 triple negative breast cancer cases suggest that A~2B~AR could serve as a prognostic biomarker and a potential therapeutic target \[[@B25-ijms-20-05139]\]. Kasama et al. \[[@B6-ijms-20-05139]\] showed that A~2B~AR controls cellular proliferation via HIF-1α activation, indicating that A~2B~AR may be a key regulator of tumoral progression in oral squamous cell carcinoma. Thus, the A~2B~AR is consistently and convincingly demonstrated to be involved in tumor cell proliferation, metastasis, angiogenesis, and immune suppression. Furthermore, the A~2B~AR and A~3~AR seem to be the only AR subtypes that are expressed in significantly higher levels in cancer tissues in comparison to normal adjacent tissues, similar to several other GPCRs \[[@B6-ijms-20-05139],[@B8-ijms-20-05139],[@B26-ijms-20-05139],[@B27-ijms-20-05139],[@B28-ijms-20-05139]\].

Although all four ARs are reported to be involved in cancer progression \[[@B16-ijms-20-05139],[@B29-ijms-20-05139],[@B30-ijms-20-05139],[@B31-ijms-20-05139]\], the other three ARs have been shown both to be pro- and anti-tumoral \[[@B16-ijms-20-05139]\]. For example, both pro- and anti-tumoral effects have been reported for the A~1~AR \[[@B16-ijms-20-05139]\]. Targeting A~2A~AR has been considered a double-edged sword \[[@B16-ijms-20-05139],[@B32-ijms-20-05139]\]. It has been suggested that adenosine accumulation in the tumor microenvironment facilitates tumor growth through the inhibition of effector T cells and natural killer (NK) cells \[[@B33-ijms-20-05139]\], and inhibition of A~2A~AR alone was found to be sufficient to establish anti-tumor immunity and protect against metastasis in various mouse models of cancer \[[@B33-ijms-20-05139]\]. However, A~2A~AR deletion does not inhibit the growth of all tumor types and might have the opposite effect. For example, an increased tumor growth rate of both B16F10 melanoma and MB49 bladder carcinomas has been observed in A~2A~AR knockout (KO) mice \[[@B5-ijms-20-05139]\]. Blocking A~2B~AR action might have advantages over the A~2A~AR as a cancer therapeutic target. Cekic et al. \[[@B5-ijms-20-05139]\] showed that AR antagonist theophylline slowed the growth of MB49 bladder and 4T1 breast tumors in mice and reduced breast cancer cell metastasis from mammary fat to the lung via the A~2B~AR, but not the A~2A~AR, based on experiments using A~2A~AR or A~2B~AR KO mice. The role of A~3~AR has been investigated in various cancer cell types with contrasting results, i.e., both pro- and anti-proliferative, as well as pro-apoptotic and anti-apoptotic effects \[[@B15-ijms-20-05139]\]. Both A~3~AR agonists and antagonists have been considered for anti-cancer agents, although only A~3~AR agonists have progressed in clinical trials \[[@B28-ijms-20-05139]\].

Recent advances in the signaling and function of the A~2B~AR \[[@B17-ijms-20-05139],[@B32-ijms-20-05139],[@B34-ijms-20-05139],[@B35-ijms-20-05139]\] and the availability of selective ligands \[[@B36-ijms-20-05139],[@B37-ijms-20-05139],[@B38-ijms-20-05139]\], have greatly facilitated understanding of the role of A~2B~AR in cancer progression and the rationale for the development of A~2B~AR antagonists as anti-tumor drugs. In this review, we first describe the distribution, signaling, agonists, and antagonists of the A~2B~AR. We then discuss the role of the A~2B~AR in the progression of various types of cancers, and the rationale of using A~2B~AR antagonists in cancer therapy.

2. A~2B~AR Distribution and Expression {#sec2-ijms-20-05139}
======================================

In rats, A~2B~AR mRNA was detected at various levels in all tissues studied \[[@B39-ijms-20-05139]\]. In mice, by replacing exon 1 of the A~2B~ gene with a reporter construct containing β-gal, mouse tissue-specific activation of the A~2B~ gene promoter was conveniently determined in various organs and specific cells within those organs, with the primary site of expression being the vasculature \[[@B40-ijms-20-05139]\]. Yang et al. \[[@B40-ijms-20-05139]\] found that mouse smooth muscle cells, endothelial cells and macrophages exhibit high A~2B~AR expression levels. The high level of A~2B~AR expression in endothelial cells suggests a potential role in angiogenesis. In human primary cells, A~2B~AR has been found in endothelial cells, mast cells, dendritic cells, macrophages, and neutrophils \[[@B17-ijms-20-05139],[@B41-ijms-20-05139]\]. High expression levels in dendritic cells and macrophages indicate a possible role in modulation of immunity. In human cancer tissues, A~2B~AR expression levels were found to be higher than in adjacent normal tissues \[[@B6-ijms-20-05139],[@B8-ijms-20-05139],[@B24-ijms-20-05139],[@B26-ijms-20-05139],[@B27-ijms-20-05139]\]. High levels of A~2B~AR have been suggested to be associated with worse prognosis in bladder urothelial carcinoma \[[@B24-ijms-20-05139]\]. Mittal et al. \[[@B7-ijms-20-05139]\] suggested that high A~2B~AR expression is associated with worse prognoses in triple-negative breast cancer (TNBC). In a TNBC mouse model, A~2B~AR activation increased metastasis \[[@B42-ijms-20-05139]\], while A~2B~AR antagonism in mouse models reduced the tumor burden by immune mechanisms and action on tumor cells. The high A~2B~AR expression has also been found in many human tumor cell lines, such as PC3 prostate, T24 bladder, 1321N1 astrocytoma \[[@B35-ijms-20-05139]\], U373MG astrocytoma \[[@B43-ijms-20-05139]\], MDA-MB-231 breast \[[@B20-ijms-20-05139]\], Jurkat T cells \[[@B44-ijms-20-05139]\], BON-1 pancreatic and KRJ-I intestinal \[[@B45-ijms-20-05139]\], A375 melanoma \[[@B46-ijms-20-05139]\], and THP-1 human monocytes \[[@B47-ijms-20-05139]\]. The high expression of the A~2B~AR in those cancer cells indicates its potential role in cancer progression. In a glioblastoma cell line derived from a mouse line containing spatially expressed A~2B~AR, this receptor is highly upregulated leading to proliferation, angiogenesis and invasiveness \[[@B48-ijms-20-05139]\]. Mouse KO of CD73, which forms adenosine locally from adenosine 5′-monophosphate (AMP), reduced A~2B~AR signaling in the glioblastoma, to decrease pathogenesis and increase sensitivity to chemotherapy. A~2B~AR expression was also demonstrated in human lung epithelial cells \[[@B49-ijms-20-05139]\]. Consistent with the high A~2B~AR expression in bladder cancer and breast cancer cells, Cekic et al. \[[@B5-ijms-20-05139]\] showed that A~2B~AR antagonists delayed the growth of bladder and breast tumors and reduced lung metastasis. Lan et al. \[[@B20-ijms-20-05139]\] found that genetic or pharmacological inhibition of A~2B~AR expression or activity dramatically impaired tumor initiation and lung metastasis in mice. Thus, high A~2B~AR expression is related to tumor growth and metastasis, and therefore A~2B~AR antagonists are potential therapeutic agents for various types of cancers including lung cancer.

3. A~2B~AR Signaling {#sec3-ijms-20-05139}
====================

Classical A~2B~AR signaling has been initially and primarily demonstrated in Chinese hamster ovary (CHO) cells expressing the recombinant human A~2B~AR \[[@B50-ijms-20-05139],[@B51-ijms-20-05139],[@B52-ijms-20-05139]\]. A~2B~AR activation leads to dissociation of the Gαs and Gβγ subunits and subsequent activation of the adenylyl cyclases, which in turn hydrolyze intracellular ATP into cyclic AMP (cAMP), which activates protein kinase A (PKA) and many downstream signaling molecules. The Gs-cAMP-PKA axis is an important A~2B~AR-mediated signaling pathway. For example, Xu et al. \[[@B53-ijms-20-05139]\] found that A~2B~AR-mediated cAMP is both necessary and sufficient to suppress interferon-γ (IFN-γ)-mediated immune responses. Jing et al. \[[@B54-ijms-20-05139]\] showed that A~2B~AR activation in hematopoietic stem cells induced chemokine (C-X-C motif) ligand 8 (CXCL8, interleukin 8) production via cAMP-PKA signaling and mediated hematopoiesis. In addition to PKA, cAMP also activates 'exchange protein directly activated by cAMP' (EPAC), another important signaling molecule related to cell migration and angiogenesis \[[@B55-ijms-20-05139]\]. In CHO cells expressing the recombinant human A~2B~AR, the nonselective AR agonist NECA 3 activated cAMP response element-binding protein (CREB) and P38 (a mitogen-activated protein kinase, MAPK) but not Akt (protein kinase B). Extracellular signal-regulated kinase 1/2 (ERK1/2) and GTPase Rap1 were blocked by PKA inhibitor H89 \[[@B52-ijms-20-05139]\]. Phosphorylation of Akt and ERK1/2 was blocked by a phosphoinositide 3-kinase (PI3K) inhibitor, wortmannin. Thus, A~2B~AR activating various downstream MAPKs may be via different signaling pathways. Although PKA-independent in CHO cells, Rap1 activation seems PKA-dependent in human embryonic kidney (HEK)293 cells \[[@B56-ijms-20-05139]\]. The coupling of A~2B~AR to β-arrestin signaling has also been reported \[[@B37-ijms-20-05139],[@B57-ijms-20-05139]\].

Most of the early studies on A~2B~AR signaling utilized CHO or HEK293 cells transfected with recombinant human A~2B~AR \[[@B51-ijms-20-05139],[@B52-ijms-20-05139]\]. However, in various types of cells endogenously expressing A~2B~AR, the receptor was able to couple to either Gi or Gs, depending on the cell type and downstream signaling pathway measured \[[@B35-ijms-20-05139]\]. For example, A~2B~AR agonist NECA stimulates ERK1/2 phosphorylation via Gαi in T24 bladder cancer cells \[[@B35-ijms-20-05139]\], but via Gαs in CHO cells \[[@B52-ijms-20-05139]\]. The Gαi inhibitor pertussis toxin, but not Gαq KO, diminished NECA-stimulated ERK1/2 activity suggesting the involvement of Gαi rather than Gαq \[[@B35-ijms-20-05139]\]. A~2B~AR downregulates ERK1/2 activity via Gαs in 1321N1 astrocytoma cells \[[@B35-ijms-20-05139]\] and in MDA-MB-231 breast cancer cells \[[@B58-ijms-20-05139]\]. ERK1/2 reduction in MDA-MB-231 cells was triggered by an A~2B~AR agonist and forskolin, but abolished by the PKA inhibitor H89, suggesting an important role for the cAMP-PKA pathway in controlling ERK1/2 activity in MDA-MB-231 cells. A~2B~AR-mediated intracellular calcium mobilization in T24 cells was mainly via Gi, although Gs may also play a minor role, but Gq is not involved \[[@B35-ijms-20-05139]\]. Thus, it is conceivable that in many cases the predominant A~2B~AR coupling is through Gαi rather than Gαs. Many important A~2B~AR functions from primary cells or tissues have recently been related to the PI3K-Akt and Ras-related protein (RAP)1B-EPAC pathways \[[@B59-ijms-20-05139],[@B60-ijms-20-05139],[@B61-ijms-20-05139],[@B62-ijms-20-05139],[@B63-ijms-20-05139]\]. However, it has not been extensively explored whether those signaling molecules are actually downstream of A~2B~AR-mediated Gαi or Gαs proteins. The A~2B~AR-mediated major signaling pathways are illustrated in [Figure 1](#ijms-20-05139-f001){ref-type="fig"}.

4. A~2B~AR Agonists and Antagonists as Pharmacological Tools {#sec4-ijms-20-05139}
============================================================

Although numerous antagonists and a few agonists for the A~2B~AR have been reported, in this section we focus on the agonists and antagonists that are commercially available as pharmacological tools and those in clinical trials for cancer patients ([Table 1](#ijms-20-05139-t001){ref-type="table"}). In addition to selective antagonists and agonists, various specialized pharmacological tools can be used to characterize A~2B~AR and its activity. Radiolabelled compounds are used to investigate A~2B~AR binding activity including both tritiated ligands and ^18^F-labeled compounds for positron emission tomography \[[@B64-ijms-20-05139],[@B65-ijms-20-05139]\]. Ligands that have been tritiated for A~2B~AR binding experiments are: agonists 3 and 8; antagonists 13, 21, 22a, and ZM241,385 (structure not shown). Fluorescent antagonists of high affinity at the A~2B~AR were recently reported \[[@B66-ijms-20-05139],[@B67-ijms-20-05139]\]. A~2B~AR allosteric modulators have been reported but not extensively characterized \[[@B36-ijms-20-05139]\].

There are two major classes of A~2B~AR agonists that are commercially available ([Figure 2](#ijms-20-05139-f002){ref-type="fig"}). The adenosine derivatives include adenosine, NECA and CPCA 4, which are considered as full and balanced agonists and often used as standard A~2B~AR agonists albeit nonselective \[[@B37-ijms-20-05139],[@B68-ijms-20-05139]\]. The non-adenosine 3,5-dicyanopyridine class of A~2B~AR agonists that are commercially available include BAY60-6583 8, LUF5834 **7** and BAY68-4986 (A~1~AR agonist Capadenoson 6). BAY60-6583 is an A~2B~AR-selective agonist but shows variable agonist E~max~ and potencies in different types of cells and tissues (\[[@B35-ijms-20-05139],[@B37-ijms-20-05139]\]. Partial and biased agonists for the A~2B~AR have been reported \[[@B34-ijms-20-05139],[@B35-ijms-20-05139],[@B37-ijms-20-05139],[@B69-ijms-20-05139],[@B70-ijms-20-05139]\]. In cAMP accumulation assays, 5′-substituted nucleosides NECA and CPCA, and non-adenosine agonists BAY60-6583 and BAY68-4986 are all full agonists in cells overexpressing the recombinant human A~2B~AR. In calcium mobilization, ERK1/2 phosphorylation and β-arrestin translocation, only 5′-substituted adenosine analogs CPCA and NECA are full agonists. A quantitative operational model characterized BAY60-6583 as an ERK1/2-biased agonist and N⁶-substituted agonists as biased against calcium and β-arrestin pathways. Interestingly, a partial A~2B~AR agonist BAY60-6583 behaved as an A~2B~AR antagonist in MIN-6 mouse pancreatic β cells expressing low A~2B~AR levels, to induce insulin release \[[@B37-ijms-20-05139]\]. It remains to be determined whether BAY60-6583 behaves as a partial agonist or an antagonist in other cell types endogenously expressing low levels of the A~2B~AR.

A~2B~AR expression levels often determine the potency and E~max~ of a given A~2B~AR agonist. BAY60-6583 was found to be a partial agonist in stimulating cAMP accumulation in several cell types endogenously expressing the A~2B~AR \[[@B37-ijms-20-05139]\]. For example, in an assay of cAMP accumulation in HEK293 cells endogenously expressing the A~2B~AR, the EC~50~ and agonist E~max~ values of BAY60-6583 are 242 nM and 73%, respectively. However, in HEK293 cells overexpressing the recombinant A~2B~AR, the EC~50~ and E~max~ of BAY60-6583 are 6.1 nM and 102%, respectively \[[@B37-ijms-20-05139]\]. BAY60-6583 did not show any agonist activity in stimulating calcium mobilization or ERK1/2 phosphorylation in T24 bladder cancer cells. BAY60-6583 also did not show any agonist activity in stimulating calcium transients in HEK293 cells, although it showed a robust effect in stimulating cAMP accumulation and ERK1/2 activity. LUF5834 has been reported as a nonselective A~2B~AR agonist showing an EC~50~ of 12 nM in cAMP accumulation and an agonist E~max~ of 74% in comparison with NECA (E~max~ = 100%) \[[@B71-ijms-20-05139]\]. Using CHO cells overexpressing the human A~2B~AR, Baltos et al. (2017) \[[@B70-ijms-20-05139]\] found that the A~1~AR agonist BAY68-4986 shows potent A~2B~AR agonist activity in stimulating cAMP accumulation, with an EC~50~ of 1.1 nM. However, when tested in cAMP accumulation in HEK293 cells endogenously expressing the A~2B~AR, BAY68-4986 showed an EC~50~ of 500 nM and E~max~ of 95% (Gao and Jacobson, unpublished data). Thus, for all nucleoside and non-nucleoside A~2B~AR agonists commercially available, only the partial agonist BAY60-6583 is A~2B~AR selective, which may show agonist activity in some signaling pathways, and antagonist properties in other signaling events \[[@B37-ijms-20-05139]\]. Full agonists selective for A~2B~AR are not yet available. Future efforts could be the development of selective and full agonists for A~2B~AR, in order to have a full range of A~2B~AR efficacies for studying cell proliferation, angiogenesis, metastasis and immune suppression.

The structures and potencies of the commercially available antagonists as pharmacological tools are listed in [Figure 2](#ijms-20-05139-f002){ref-type="fig"} and [Table 1](#ijms-20-05139-t001){ref-type="table"}, respectively. The first selective A~2B~AR antagonists were reported by \[[@B72-ijms-20-05139]\], which were xanthine derivatives, and currently there are chemically diverse heterocyclic selective A~2B~AR antagonists, such as recently reported LAS101053 25, AB928 26 and ISAM140 27 \[[@B3-ijms-20-05139],[@B36-ijms-20-05139]\]. Commercially available A~2B~AR antagonists as pharmacological tools include 8-arylxanthine derivatives MRS1754 13, MRS1706 14, GS6201 18, PSB-1115 21, PSB-603 22a and PSB-0788 23. Recently, an alkylxanthine with a picomolar affinity at the human A~2B~AR, PSB-1901 22b, was reported \[[@B73-ijms-20-05139]\]. Antagonists that are in clinical trials (AB928 26, PBF-1129 and theophylline 11) will be discussed in [Section 9](#sec9-ijms-20-05139){ref-type="sec"}.

5. A~2B~AR in Cell Proliferation and Tumor Growth {#sec5-ijms-20-05139}
=================================================

A~2B~AR activation can promote proliferation of multiple types of cancer cells and growth of solid tumors. Activation of the A~2B~AR by BAY 60--6583 was shown to stimulate both proliferation and migration of MDA-MB-231 cells \[[@B78-ijms-20-05139]\]. The A~2B~AR-mediated effects were blocked by an A~2B~AR antagonist GS-6201. Wei et al. \[[@B1-ijms-20-05139]\] found the A~2B~AR to be the most highly expressed AR in several human prostate cancer cell lines, including PC-3, and A~2B~AR activation promotes cell proliferation and decreases cell apoptosis. An A~2B~AR-selective antagonist PSB-603 decreased proliferation of prostate cancer cell lines \[[@B4-ijms-20-05139],[@B79-ijms-20-05139]\], and colon cancer cells \[[@B21-ijms-20-05139]\]. Activation of the A~2B~AR with agonist BAY 60-6583 increased tumor growth in a mouse model of melanoma \[[@B10-ijms-20-05139]\]. In a model of bladder cancer, inhibition of tumor growth by the non-selective antagonist theophylline was demonstrated to be mediated by A~2B~AR but not A~2A~AR blockade \[[@B5-ijms-20-05139]\]. A~2B~AR selective antagonist ATL801 also inhibited growth of MB49 bladder and 4T1 breast tumor volume \[[@B5-ijms-20-05139]\] and melanoma in mice \[[@B10-ijms-20-05139]\]. Stagg et al. \[[@B80-ijms-20-05139]\] showed that A~2B~AR activation promoted 4T1.2 tumor-cell chemotaxis in vitro and metastasis in vivo. High A~2B~AR expression levels have also been found in hepatocellular carcinoma \[[@B27-ijms-20-05139]\]. It has been suggested that high A~2B~AR levels are generally associated with worse prognosis or poor survival \[[@B7-ijms-20-05139],[@B17-ijms-20-05139]\].

The results from A~2B~AR blockade with antagonists were consistent with those from genetic knockdown and KO of the A~2B~AR in various animal models of solid tumors \[[@B5-ijms-20-05139],[@B6-ijms-20-05139],[@B9-ijms-20-05139]\], further confirming the critical role of this receptor in cancer cell proliferation and growth.

The specific mechanisms related to A~2B~AR-mediated proliferation of various cancer cells and growth of different types of tumors have not been extensively and systematically explored. As it has been suggested that different agonists may bind in different modes and induce different A~2B~AR conformational changes \[[@B81-ijms-20-05139]\], together with the recent finding that A~2B~AR may couple variably to at least three G proteins in different cell types, it is possible that each agonist may activate a particular mix of signaling cascades in a specific cell type, or the same agonist may activate different signaling pathways in other cell types \[[@B35-ijms-20-05139]\]. Thus, the signaling mechanisms related to A~2B~AR-mediated cell proliferation may be diverse in different types of cancers. Nevertheless, multiple studies have shown the importance of several signaling pathways related to A~2B~AR activation and the subsequent release of various cytokines and growth factors, which eventually led to cancer cell proliferation. MAPK signaling is involved in multiple cellular processes and is often active in cancer cells, promoting proliferation and metastasis \[[@B82-ijms-20-05139]\]. A~2B~AR was demonstrated to couple to all three types of MAPKs \[[@B52-ijms-20-05139]\], the extracellular signal-regulated kinases (ERK1/2), the stress-activated protein kinases P38 and the c-jun N-terminal kinase (JNK). The cAMP-EPAC pathway and ERK1/2 phosphorylation are known to be involved in A~2B~AR-mediated proliferation of some endothelial cells \[[@B55-ijms-20-05139],[@B83-ijms-20-05139]\]. Limm et al., \[[@B61-ijms-20-05139]\] showed that PKC, but not cAMP or Ca^2+^, is involved in 5′-methylthioadenosine (2)-induced and A~2B~AR-mediated melanoma cell proliferation. Forskolin can mimic adenosine-induced proliferation of MDA-MB-231 breast cancer cells, suggesting that Gs-cAMP signaling is involved, although it is not clear whether PKA or EPAC is the downstream mediator. Recent evidence correlates the A~2B~AR-mediated cAMP/PKA and MAPK/ERK pathway activation with the epithelial-mesenchymal transition in lung cancer cells \[[@B49-ijms-20-05139]\]. A~2B~AR has been shown to activate the PI3K-Akt pathway \[[@B52-ijms-20-05139]\], which is known to induce cell proliferation and protects against apoptosis in many cancer cell types. The A~2B~AR-mediated PI3K-Akt pathway has been shown to be critical for proliferation of glioblastoma stem cells \[[@B84-ijms-20-05139]\]. The importance of Akt signaling in cell survival has been demonstrated in many cell types. However, it remains to be investigated whether the A~2B~AR-mediated PI3K-Akt pathway is downstream of Gαi, Gαs or both.

6. A~2B~AR and Tumor Metastasis {#sec6-ijms-20-05139}
===============================

A~2B~AR activation plays a critical role in cell motility and migration, which are part of the multi-step process of metastasis \[[@B8-ijms-20-05139],[@B56-ijms-20-05139],[@B85-ijms-20-05139]\]. Adenosine binding to A~2B~AR on tumor cells was found to enhance their metastatic capability \[[@B56-ijms-20-05139],[@B86-ijms-20-05139]\]. It was reported that the A~2B~AR has higher expression in metastatic versus non-metastatic derived colorectal cancer cell lines \[[@B21-ijms-20-05139]\]. A~2B~AR activation has been shown to enhance tumor cell chemotaxis and lung metastasis in animal models of breast cancer and melanoma \[[@B5-ijms-20-05139],[@B7-ijms-20-05139],[@B80-ijms-20-05139]\]. This is consistent with A~2B~AR agonist-induced metastasis, A~2B~AR-selective antagonists and genetic knockdown with shRNA suppressed lung metastasis \[[@B5-ijms-20-05139],[@B7-ijms-20-05139],[@B87-ijms-20-05139]\].

The mechanisms behind A~2B~AR-mediated cell migration and metastasis have been explored \[[@B56-ijms-20-05139]\]. A~2B~AR-mediated cell motility and metastasis is related to the PKA-dependent suppression of Rap1B, a Rho member of the Ras superfamily of small GTPases that activate MAP kinases \[[@B56-ijms-20-05139]\]. It was found that A~2B~AR activation may delay Rap1B prenylation in breast, lung, and pancreatic cancer cell lines, and suggested that A~2B~AR inhibition may be an effective method to prevent metastasis. Similarly, Wilson et al. \[[@B88-ijms-20-05139]\] found that another Gs-coupled GPCR family, the β-adrenergic receptors, suppresses Rap1B prenylation via a PKA-dependent mechanism and promotes the metastatic phenotype in MDA-MB-231 breast cancer cells. Desmet et al. \[[@B87-ijms-20-05139]\] suggested that the enhanced metastasis may involve A~2B~AR-increased gene expression of a key metastatic transcription factor, Fos-related antigen-1 (Fra-1), the expression level of which is associated with increased cell motility and invasion \[[@B89-ijms-20-05139],[@B90-ijms-20-05139]\]. Fra-1 is regulated by ERK, and its overexpression is associated with a poor clinical outcome \[[@B91-ijms-20-05139]\]. Fra-1 and A~2B~AR positively correlate at the mRNA level, and it was shown using chromatin immunoprecipitation (ChIP) experiments that Fra-1 binds the promoter of the A~2B~AR gene in human breast cancer cells \[[@B87-ijms-20-05139]\]. Ou et al. \[[@B59-ijms-20-05139]\] discovered that hypoxia, as well as extracellular ATP, causes a reversible increase in the centrosome-nucleus distance and reduced cell motility through the A~2B~AR and specifically activates the Epac1/RapGef3 pathway. Epac1 is critically involved, and Rap1B is important in the relative positioning of the centrosome and nucleus, which is related to cell motility and migration.

7. A~2B~AR and Angiogenesis {#sec7-ijms-20-05139}
===========================

Tumor growth is enhanced by angiogenesis, the formation of new blood vessels, which involves the migration, differentiation and growth of endothelial cells inside the blood vessels. Adenosine signaling plays an important role in angiogenesis. Adenosine has been reported to promote angiogenic responses via all four AR subtypes \[[@B28-ijms-20-05139],[@B92-ijms-20-05139],[@B93-ijms-20-05139],[@B94-ijms-20-05139]\]. The endothelial cells express high levels of the A~2B~AR suggesting its potentially critical role in promoting angiogenesis. A~2B~AR stimulation promotes the production of angiogenic cytokines by mast cells \[[@B9-ijms-20-05139]\] and dendritic cells \[[@B95-ijms-20-05139]\]. It has been suggested that adenosine increases endothelial cell proliferation, chemotaxis and capillary tube formation \[[@B83-ijms-20-05139],[@B96-ijms-20-05139]\]. A~2B~AR activation has also been shown to stimulate production of vascular endothelial growth factor (VEGF), basic fibroblast growth factor and insulin-like growth factor-1 (IGF1) by human microvascular endothelial (HMEC)-1 cells \[[@B23-ijms-20-05139]\]. Adenosine was demonstrated to promote VEGF production in rat myocardial myoblasts \[[@B97-ijms-20-05139]\] and in macrophages from C57BL/6 mice \[[@B98-ijms-20-05139]\] It has been demonstrated that AR stimulation could increase VEGF production five-fold in tumor-associated CD45^+^ immune cells, an effect that is not observed in CD45^+^ cells from A~2B~AR KO mice \[[@B96-ijms-20-05139]\] The A~2B~AR induces production of VEGF \[[@B23-ijms-20-05139],[@B96-ijms-20-05139],[@B99-ijms-20-05139]\] and interleukin (IL)-8 in human melanoma cells \[[@B46-ijms-20-05139]\], which are essential for tumor angiogenesis. Bay60-6583, a selective A~2B~AR agonist, was demonstrated to induce in tumor expression of VEGF-A \[[@B100-ijms-20-05139]\]. A~2B~AR inhibition by a selective antagonist PSB-1115 21 significantly decreased tumor growth by blocking angiogenesis and increasing T cells numbers within the tumor microenvironment.

Multiple signaling molecules have been found to be related to A~2B~AR-mediated angiogenesis. Du et al. \[[@B101-ijms-20-05139]\] suggested the A~2B~AR activation-driven angiogenesis is via cAMP-PKA-CREB mediated VEGF production and PI3K/Akt-dependent upregulation of endothelial nitric oxide synthase (eNOS) in HMEC-1 cells. Ryzhov et al. \[[@B97-ijms-20-05139]\] suggested that VEGF appears to be stimulated by a mechanism involving the transcription factor JunB downstream of A~2B~AR-mediated PLC-Rap1-MEK activation. Fang and Olah \[[@B55-ijms-20-05139]\] showed that cyclic AMP-dependent, protein kinase A-independent activation of ERK1/2 following AR stimulation in human umbilical vein endothelial cells was via Epac1.

8. A~2B~AR and Immunity {#sec8-ijms-20-05139}
=======================

It has been well documented that cancer cells can escape from anti-tumor immune surveillance especially under conditions with impaired immunity. Adenosine has demonstrated its role as an important modulator of immune cell functions at least in part via its action at the A~2B~AR \[[@B17-ijms-20-05139],[@B32-ijms-20-05139],[@B41-ijms-20-05139]\]. A~2B~AR activation is known to suppress IFN-γ-enhanced expression of major histocompatibility complex class II (MHC-II) transactivator \[[@B53-ijms-20-05139],[@B102-ijms-20-05139]\]. In addition to the well-described roles of CD73 and CD39, adenosine deaminase is known to control the local adenosine concentration, and this enzyme also binds to the A~2B~AR \[[@B103-ijms-20-05139]\] Adenosine deaminase deficiency is one of the serious immune diseases which is due to the increased adenosine concentration and subsequently suppressed immune responses. Thus, in addition to its direct effects on metastasis, proliferation and angiogenesis, the A~2B~AR can have a direct or an indirect role on cancer progression via modulation of the immune system. The role of the A~2B~AR in cell immunity was mostly neglected until recently partly due to adenosine having a low A~2B~AR affinity \[[@B11-ijms-20-05139],[@B12-ijms-20-05139]\], although early findings indicated that A~2B~AR was the AR subtype responsible for the immune suppressive function of T cells, macrophages and dendritic cells \[[@B11-ijms-20-05139],[@B17-ijms-20-05139],[@B41-ijms-20-05139]\]. Also, early work on CD26/DPP4 (dipeptidyl peptidase 4), a T cell surface antigen that cleaves various bioactive peptides, mainly focused on its role in T cells \[[@B104-ijms-20-05139],[@B105-ijms-20-05139]\] that highly express the A~2A~AR \[[@B106-ijms-20-05139],[@B107-ijms-20-05139],[@B108-ijms-20-05139]\]. More recently, in addition to CD39 and CD73, the importance of A~2B~AR and DPP4 in dendritic cells and macrophages also gained appreciation \[[@B47-ijms-20-05139]\]. DPP4 has been identified as one of the macrophage-related gene signatures predicative of increased risk in gliomas \[[@B109-ijms-20-05139]\]. DPP4 inhibitor vildagliptin has been reported to suppress lung cancer growth via a macrophage-mediated mechanism \[[@B110-ijms-20-05139]\]. Considering the increased adenosine concentration and increased A~2B~AR expression in the tumor microenvironment \[[@B17-ijms-20-05139],[@B31-ijms-20-05139],[@B100-ijms-20-05139]\] together with the high expression levels of both A~2B~AR and DPP4 in macrophages and dendritic cells, growing evidence suggests a critical role of A~2B~AR together with CD39 and CD73 in modulating cancer progression at least in part via immune suppression. Furthermore, DPP4 physically associates with adenosine deaminase, which controls adenosine concentration and binds to the A~2B~AR. Thus, A~2B~AR blockade may enhance the function of immune cells \[[@B17-ijms-20-05139],[@B31-ijms-20-05139],[@B41-ijms-20-05139]\].

A~2A~AR has been shown to be critical in regulating toll-like receptor (TLR)-induced cytokine production. However, a recent study utilizing macrophages isolated from A~2B~AR KO mice showed that adenosine elicits IL-6 production from macrophages via the A~2B~AR \[[@B19-ijms-20-05139]\]. IFN-γ upregulates A~2B~AR expression on macrophages resulting in an increased responsiveness of macrophages to the stimulatory effects of NECA \[[@B111-ijms-20-05139]\]. The pharmacologic inhibition or the genetic deletion of the A~2B~AR results in a hyperinflammatory response to TLR ligation, similar to IFN-γ treatment of macrophages, suggesting the NECA-mediated effect is via A~2B~AR, but not A~2A~AR \[[@B111-ijms-20-05139]\]. The role of A~2B~AR in regulating dendritic cell function has been defined using A~2B~AR KO mice and selective agonists and antagonists for A~2B~AR \[[@B17-ijms-20-05139],[@B41-ijms-20-05139]\]. In mice bearing MB49 and/or 4T1 tumors, Cekic et al. \[[@B5-ijms-20-05139]\] demonstrated that selective blockade of A~2B~AR resulted in a C-X-C chemokine receptor 3 (CXCR3)-dependent reduction of tumor growth and lung metastases from breast tumors through enhancement of dendritic cell activation. Inhibition of A~2B~AR activation by PSB-603 was shown to suppress regulatory T cell (Treg) differentiation and IL-10 production, without affecting effector T cell activation measured by IL-2 production and CD25 expression \[[@B112-ijms-20-05139]\]. A~2B~AR was also suggested to modulate the phenotype of bone marrow-derived dendritic cells. A~2B~AR activation impairs MHC-II transcription in IFN-γ-stimulated cells \[[@B113-ijms-20-05139],[@B114-ijms-20-05139]\]. MHC-II expression is required for CD4^+^ T cell anti-tumor responses, and loss of MHC-II is associated with aggressiveness of colorectal cancer and decreased levels of tumor-infiltrating lymphocytes \[[@B115-ijms-20-05139]\]. Shi et al. \[[@B116-ijms-20-05139]\] also reported that both major MHC-II transactivator (CIITA) and MHC-II are decreased in highly metastatic cancer cells. Thus, A~2B~AR blockade has the potential to enhance anti-tumor immunity in cancers where tumor-infiltrating lymphocytes and MHC-II levels are decreased.

The specific signaling pathways related to A~2B~AR-mediated immune suppression have been explored. Xu et al. \[[@B53-ijms-20-05139]\] found that A~2B~AR-mediated cAMP is both necessary and sufficient to suppress the IFN-γ-mediated immune response. Figueiredo et al. \[[@B117-ijms-20-05139]\] showed that cAMP accumulation induced by A~2B~AR activation is important to inhibit dendritic cell activation and to evade the immune response in infected mice. In human monocytes, it has been suggested that A~2B~AR-triggered cAMP accumulation inhibits the immune response by lowering the amount of MHC class I and class II molecules \[[@B118-ijms-20-05139]\]. A~2B~AR-induced cAMP accumulation was also found to reduce STAT1 phosphorylation and impair its binding to the CIITA promoter while fostering synthesis of TGF-β, known to antagonize MHC-II transactivation \[[@B113-ijms-20-05139],[@B114-ijms-20-05139]\]. Iannone et al. \[[@B10-ijms-20-05139]\] showed that melanoma-bearing mice treated with the selective A~2B~AR agonist BAY60-6583 had increased melanoma growth, which was associated with higher levels of immune regulatory mediators IL-10 and monocyte chemoattractant protein 1 and accumulation of tumor-associated CD11b+ and Gr1+ cells and myeloid-derived suppressor cells. Depletion of CD11b+Gr1+ cells completely reversed the pro-tumor activity of BAY60-6583. Inhibition of A~2B~AR with PSB-1115 reversed immune suppression in the tumor microenvironment, leading to a significant delay in melanoma growth. The authors suggest that the antitumor activity of PSB-1115 relies on its ability to lower accumulation of tumor-infiltrating myeloid-derived suppressor cells (MDSCs) and restore an efficient antitumor T cell response.

9. A~2B~AR Antagonists as Novel Anticancer Agents {#sec9-ijms-20-05139}
=================================================

As described above, A~2B~AR activation induces tumor proliferation, growth of solid tumor, tumor angiogenesis, tumor cell invasion and metastasis, and immune suppression. Thus, A~2B~AR blockade holds great promise as an anti-cancer therapy. For example, A~2B~AR inhibition by the antagonist PSB-1115 was shown to decrease tumor metastasis of CD73^+^ melanoma cells and mammary carcinoma cells \[[@B7-ijms-20-05139]\] Iannone et al. \[[@B10-ijms-20-05139]\] observed that PSB-1115 delayed tumor growth and enhanced the anti-tumor activity of dacarzabine, a drug currently used in metastatic melanoma.

Cekic et al. \[[@B5-ijms-20-05139]\] demonstrated that the antitumor effect of theophylline occurs via the A~2B~AR rather A~2A~AR, based on a study using A~2A~ and A~2B~AR KO mice. Nevertheless, simultaneous antagonism of both subtypes has been proposed to be possibly synergistic against some types of tumors \[[@B17-ijms-20-05139],[@B32-ijms-20-05139]\], although it is not clear whether the blockade of both A~2A~AR and A~2B~AR could also produce more adverse effects than either subtype separately.

Antagonists in clinical trials for cancer patients (ClinicalTrials.gov NCT Identifier) include the mixed A~2A~AR/A~2B~AR antagonist AB928 26 (Phase 1, lung cancer, 03846310; Phase 1, breast and ovarian cancer, 03719326; Phase 1, gastrointestinal cancer, 03720678; Phase 1, advanced cancer, 03629756), PBF-1129 (structure not disclosed; Phase 1, non-small cell lung cancer, 03274479) and theophylline 11 (see below). The first dual-acting A~2A~AR/A~2B~AR antagonist AB928 is being tested clinically in multiple arms in combination with pegylated liposomal doxorubicin, nanoparticle albumin-bound paclitaxel, or a PI3K-γ inhibitor. AB928 has exhibited excellent safety, PK, and PD profiles in a Phase 1 clinical trial in healthy volunteers and is currently being evaluated in patients with non-small cell lung cancer, breast cancer, ovarian cancer, colorectal and six other types of cancers (clinicaltrials.gov). One of the cancer immunotherapy drugs, AB122, a fully human immunoglobulin G4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1), will be tried in combination with AB928. AB928 was able to produce maximal AR blockade assessed as a function of NECA-stimulated pCREB induction in peripheral blood CD8+ T cells \[[@B3-ijms-20-05139]\]. AB928 was shown to relieve adenosine-mediated immune suppression \[[@B76-ijms-20-05139]\]. Combining AR inhibition with AB928 and chemotherapy results in greater immune activation and tumor control.

A phase I trial of the selective A~2B~AR antagonist PBF-1129 (structure not disclosed) in patients with advanced non-small cell lung cancer is being conducted. PBF-1129 is being administered in a dose escalation study of tolerability without other therapy.

Theophylline is a nonselective AR antagonist, which was tested for anticancer efficacy in two previous clinical trials (incidentally, as an inhibitor of intracellular cAMP in chronic lymphocytic leukemia, Phase 2, 00003808; a withdrawn trial in combination with an allogeneic tumor cell-vaccine (gp96-Ig vaccine) and oxygen therapy, which lowers adenosine levels \[[@B119-ijms-20-05139]\], in non-small cell lung cancer, Phase 1, 01799161). The first theophylline trial description did not even reference AR antagonism, but there was a correlation found between in vitro apoptosis in leukemia cells and clinical response in a subset of patients \[[@B120-ijms-20-05139]\]. Theophylline in combination prednisone and dextromethorphan has also been in a clinical trial (Phase 1, 01017939) for patients with metastatic castration-resistant prostate cancer. Aminophylline, a salt of theophylline, in combination with Bacillus Calmette-Guerin has been in a trial (early Phase 1, 01240824) for patients with bladder cancer. However, it should be noted that theophylline is nonselective and may block all four ARs.

10. Summary {#sec10-ijms-20-05139}
===========

A~2B~AR signaling is a major pathway contributing to cancer cell proliferation and solid tumor growth, angiogenesis and metastasis, and immune suppression. Thus, A~2B~AR antagonists are potentially a novel anticancer therapy, either in combination with other anticancer drugs or as a mono-therapy. Several A~2B~AR antagonists are now in clinical trials for patients with various types of cancers. The nonselective A~2B~AR antagonist, theophylline, in combination with other anticancer drugs has been evaluated in patients with bladder cancer and prostate cancer. Dual acting A~2A~AR/A~2B~AR antagonist AB928 has exhibited excellent safety, PK, and PD profiles in a Phase 1 clinical trial in healthy volunteers and is currently being evaluated in patients with non-small cell lung cancer, breast cancer and ovarian cancer. A~2B~AR selective antagonist PBF-1129 is also in clinical trial for patients with non-small cell lung cancer. Thus, A~2B~AR antagonism is a promising direction for the development of new cancer therapeutics.
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![A~2B~ adenosine receptor (AR) signaling in mammalian cells and in the tumor microenvironment, as explained in the text. The three G proteins shown act through either G α, e.g., on cyclic AMP (cAMP), or G β, γ subunits, e.g., on phosphoinositide 3-kinase (PI3K). Protein kinase A (PKA) has either a stimulatory or inhibitory effect on extracellular signal-regulated kinase 1/2 (ERK1/2). For more detail see: \[[@B15-ijms-20-05139],[@B35-ijms-20-05139],[@B49-ijms-20-05139],[@B56-ijms-20-05139],[@B58-ijms-20-05139]\]. For effects on specific immune cells, see \[[@B17-ijms-20-05139],[@B32-ijms-20-05139]\].](ijms-20-05139-g001){#ijms-20-05139-f001}

![Chemical structures of both commercially available and literature-reported A~2B~AR agonists (1--10) and antagonists (11--27) as pharmacological tools and an A~2A~AR/A~2B~AR mixed antagonist (26) in a clinical trial for cancer treatment. For more detail, see \[[@B36-ijms-20-05139],[@B37-ijms-20-05139]\].](ijms-20-05139-g002){#ijms-20-05139-f002}
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###### 

Binding affinity (K~i~, nM) or functional potency (EC~50~, nM; E~max~ as %) of commercially available A~2B~AR agonists and antagonists as pharmacological tools and A~2B~AR antagonists in clinical trials for cancer patients. Refer to [Figure 2](#ijms-20-05139-f002){ref-type="fig"} for structures. K~i~ (nM) or EC~50~ (E~max~, %)

  Compound                    A~1~       A~2A~      A~2B~             A~3~       Reference
  --------------------------- ---------- ---------- ----------------- ---------- --------------------------
  *Agonists*                                                                     
  1, Adenosine ^a^            310        700        24,000            290        \[[@B68-ijms-20-05139]\]
                                                    4620 ^c^ (97%)               \[[@B37-ijms-20-05139]\]
  3, NECA ^b^                 14         20         1900              25         \[[@B38-ijms-20-05139]\]
  3, NECA ^a^                 12         60         104 (100%)        11         \[[@B71-ijms-20-05139]\]
  4, CPCA                     1.9^b^     50^b^      267 ^c^ (102%)    108 ^b^    \[[@B37-ijms-20-05139]\]
  6, BAY68-4986 ^a^           0.66       1400       1.1 (93%)         2400       \[[@B70-ijms-20-05139]\]
  (Capadenoson)                                     522 ^c,d^ (95%)              
  7, LUF5834                  2.6 ^b^    28 ^b^     12 ^a^ (74%)      538 ^b^    \[[@B71-ijms-20-05139]\]
  8, BAY60-6583 ^b^           390        \>10,000   110               220        \[[@B38-ijms-20-05139]\]
                                                    242 ^c^ (73%)                \[[@B37-ijms-20-05139]\]
                                                    6.1 ^e^ (102%)               \[[@B37-ijms-20-05139]\]
  *Antagonists*                                                                  
  11, Theophylline ^b^        6200       1710       7850              22,300     
  12, Caffeine ^b^            44,900     9560       33,800            13,300     \[[@B38-ijms-20-05139]\]
  13, MRS1754 ^b^             403        503        1.7               570        \[[@B38-ijms-20-05139]\]
  14, MRS1706 ^b^             157        112        1.4               230        \[[@B38-ijms-20-05139]\]
  18, GS6201 ^b^ (CVT-6833)   1940       3280       22                1070       \[[@B74-ijms-20-05139]\]
  21, PSB-1115 ^b^            \>10,000   3790       53.4              \>10,000   \[[@B38-ijms-20-05139]\]
  22a, PSB-603 ^b^            \>10,000   \>10,000   0.55              \>1000     \[[@B38-ijms-20-05139]\]
  22b, PSB-1901 ^b^           \>1000     \>1000     0.060             \>1000     \[[@B73-ijms-20-05139]\]
  23, PSB-0788 ^b^            2240       333        0.39              \>1000     \[[@B38-ijms-20-05139]\]
  27, LAS101057 ^b^           \>10,000   2500       24                \>10,000   \[[@B75-ijms-20-05139]\]
  26, AB928 ^b^               64         1.5        2.0               489        \[[@B76-ijms-20-05139]\]
  27, ISAM140^b^              \>10,000   \>10,000   0.55              \>1000     \[[@B77-ijms-20-05139]\]
  PBF-1129                    nd         nd         nd                nd         

^a^ EC~50~ values (nM) from cAMP assays. ^b^ K~i~ values (nM) from radioligand binding. ^c^ EC~50~ values (nM) from cAMP assays in human embryonic kidney (HEK)293 cells endogenously expressing the A~2B~AR. ^d^ unpublished data. ^e^ The EC~50~ and E~max~ values of Bay60-6583 stimulated cAMP accumulation in HEK293 cells expressing the recombinant human A~2B~AR \[[@B37-ijms-20-05139]\]; Percentages shown in the A~2B~ column represent the agonist E~max~ in comparison to NECA as 100%. nd, not disclosed.
